[Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study].
The efficacy and tolerance of zotepine and haloperidol were examined in 40 patients suffering from paranoid schizophrenia (DSM III). The study period was 6 weeks. Psychopathology was assessed with BPRS and CGI. Documentation of side effects was done with DOTES. The safety parameters were pulse, blood pressure, leucocyte count, liver enzymes, ECG and EEG, determined at different times. Both treatment groups improved significantly without any differences in respect to efficacy. The patients who had been treated with zotepine had significantly fewer extrapyramidal side effects. However, transient increases in liver enzyme levels were seen more frequently in the zotepine group. There were no differences between the groups in respect to other side effects.
Fleischhacker
W W
WW
Arbeitsgruppe für Biologische Psychiatrie, Universität Innsbruck, Osterreich.
Barnas
C
C
Stuppäck
C H
CH
Sperner-Unterweger
B
B
Miller
C
C
Hinterhuber
H
H
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003988:Dibenzothiepins / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D008297:Male; D009460:Neurologic Examination; D011569:Psychiatric Status Rating Scales; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000523:psychology
D014150:Antipsychotic Agents; D003988:Dibenzothiepins; D006220:Haloperidol; C022172:zotepine
Zotepin vs. Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie.